Search

Your search keyword '"Parvaneh Shadara"' showing total 2 results
Start Over Author "Parvaneh Shadara"
2 results on '"Parvaneh Shadara"'

1. Hearing function after betahistine therapy in patients with Ménière's disease

Author

Seyed Javad Seyed Tootoonchi, Samad Ghiasi, Parvaneh Shadara, Simin Mirakhor Samani, and Daniel Fadaei Fouladi

Subjects
Medical treatment, Ménière's disease, Hearing loss, Prognosis, Otorhinolaryngology, RF1-547
Abstract

ABSTRACT INTRODUCTION: Preventing or reversing hearing loss is challenging in Ménière's disease. Betahistine, as a histamine agonist, has been tried in controlling vertigo in patients with Ménière's disease, but its effectiveness on hearing problems is not known. OBJECTIVE: To examine the effect of betahistine on hearing function in not-previously-treated patients with Ménière's disease and to define possible contributors in this regard. METHODS: A total of 200 not-previously-treated patients with definite unilateral Ménière's disease received betahistine by mouth (initial dose, 16 mg three times a day; maintenance dose, 24-48 mg daily in divided doses). Changes in indicators of hearing status before and six months after treatment were documented. Hearing loss was considered as the mean hearing level >25 dB HL at five frequencies. RESULTS: The mean duration of disease was 3.37 years. Six months after treatment the mean hearing level decreased by 6.35 dB compared to that at the baseline (p < 0.001). Both patients' age and the duration of disease correlated negatively with the improvement in hearing function. Post treatment hearing loss was independently associated with age, the initial hearing level and the chronicity of disease. The corresponding optimal cut-off points for predicating a persistent hearing loss 6 months after treatment were 47 years, 38 dB HL, and 1.4 years, respectively. CONCLUSION: Oral betahistine was significantly effective in preventing/reversing hearing deterioration in patients with Ménière's disease. Age, the hearing level on admission, and the disease duration were independent predictors of hearing status after treatment.

Full Text
View/download PDF

2. New therapy for chemotherapy-induced hepatic failure in leukemia; a randomized double-blind clinical trial study

Author

Javad Rasouli, Parvaneh Shadara, Mehran Noroozi, Sasan Hejazi, and Farid Ghazizadeh

Subjects
medicine.medical_specialty, hepatotoxicity, genetic structures, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Immunology, acute lymphoblastic leukemia, Placebo, chemotherapy, Breast cancer, Immunology and Microbiology (miscellaneous), milk thistle, Internal medicine, Medicine, Chemotherapy, Milk Thistle, business.industry, Hematology, medicine.disease, Discontinuation, Clinical trial, Leukemia, Liver function, business
Abstract

Introduction: Hepatotoxicity is usual toxicity after chemotherapy in acute lymphoblastic leukemia (ALL) patients. Conventional treatment methods such as supportive care did not have an effective role in the improvement of hepatotoxicity. Objectives: In this study clinical efficacy of milk thistle in contrast with placebo was compared in leukemia patients with chemotherapy-induced hepatotoxicity. Patients and Methods: In this double-blind study, 93 ALL patients with chemotherapy-induced hepatotoxicity were randomized to a clinical trial with milk thistle or placebo. Liver enzymes level evaluated during 70 days. We divided patients randomly into two groups. Milk thistle at dosage of 7 mg/kg daily was prescribed in the intervention group while in the control group, placebo pills similar to milk thistle in shape and color were prescribed daily. Results: At day 35 and day 70 of the study, in the milk thistle arm ALT and AST mean serum levels were lower than the placebo group (PConclusion: Based on our results, milk thistle improves liver function in chemotherapy-induced hepatotoxicity and there was no need for dose reduction or discontinuation of chemotherapy. Future clinical trials should be conducted to explore longtime effect of livergol in leukemia patients and to determine if there is any need for prophylactic administration of antioxidants. Trial Registration: This clinical trial has been approved by the Iranian Registry of Clinical Trials at 2018-02-14 (identifier: IRCT20170821035831N2; http://en.irct.ir/trial/26957).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results